NASDAQ:FLXN

Flexion Therapeutics Stock Insider Trading

> Drug Manufacturers - Specialty & Generic

Buy FLXN

*Your capital is at risk

$24.94

-0.1000 (-0.399%)

At Close: Jun 03, 2026

Flexion Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 16.56M FLXN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	0 shares
● Sell	16.56M shares
2% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 19, 2021 Sell	Common Stock, par value $0.001 per share U-Tender	Newtyn Management, Llc 10 Percent Owner	10% Owner	5 900 000 Value: $50.2M
Nov 19, 2021 Sell	Common Stock, par value $0.001 per share U-Tender	Newtyn Management, Llc 10 Percent Owner	10% Owner	5 900 000 Value: $50.2M
Nov 19, 2021 Sell	Common Stock D-Return	Stejbach Mark Director	Director	12 631 Value: $107.4K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Stejbach Mark Director	Director	25 000 Value: $396.8K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Stejbach Mark Director	Director	12 500 Value: $252.0K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Stejbach Mark Director	Director	12 500 Value: $351.8K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Stejbach Mark Director	Director	12 500 Value: $146.8K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Stejbach Mark Director	Director	7 000 Value: $83.2K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Stejbach Mark Director	Director	7 000 Value: $64.5K
Nov 19, 2021 Sell	Common Stock D-Return	Merrifield C Ann Director	Director	19 000 Value: $161.5K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	18 000 Value: $229.0K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	9 000 Value: $196.7K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	12 500 Value: $172.9K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	12 500 Value: $252.0K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	12 500 Value: $351.8K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	12 500 Value: $146.8K
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Merrifield C Ann Director	Director	7 000 Value: $83.2K
Nov 19, 2021 Sell	Performance Restricted Stock Unit Award D-Return	Clayman Michael D. President And CEO	CEO / President	106 100 Value: $0
Nov 19, 2021 Sell	Stock Option (right to buy) D-Return	Clayman Michael D. President And CEO	CEO / President	290 000 Value: $4.28M
Nov 19, 2021 Sell	Stock Option (right to buy) D-Return	Clayman Michael D. President And CEO	CEO / President	175 000 Value: $3.25M
Nov 19, 2021 Sell	Stock Option (right to buy) D-Return	Clayman Michael D. President And CEO	CEO / President	155 000 Value: $2.82M
Nov 19, 2021 Sell	Stock Option (right to buy) D-Return	Clayman Michael D. President And CEO	CEO / President	116 667 Value: $2.60M
Nov 19, 2021 Sell	Stock Option (right to buy) D-Return	Clayman Michael D. President And CEO	CEO / President	185 000 Value: $2.92M
Nov 19, 2021 Sell	Common Stock D-Return	Levine Mark S. General Counsel	Officer	133 486 Value: $1.13M
Nov 19, 2021 Sell	Stock option (right to buy) D-Return	Mahaffy Patrick J Director	Director	12 500 Value: $115.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FLEXION THERAPEUTICS INC.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a sustained-release intra-articular steroid, which is in clinical trials to treat the patients with moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a...

Read Full Profile Here